369 related articles for article (PubMed ID: 35777877)
1. Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study).
Mutubuki EN; van der Maaden T; Leung KY; Wong A; Tulen AD; de Bruijn S; Haverman L; Knoop H; Franz E; van Hoek AJ; van den Wijngaard CC
BMJ Open; 2022 Jul; 12(7):e062439. PubMed ID: 35777877
[TBL] [Abstract][Full Text] [Related]
2. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021.
; Wulf Hanson S; Abbafati C; Aerts JG; Al-Aly Z; Ashbaugh C; Ballouz T; Blyuss O; Bobkova P; Bonsel G; Borzakova S; Buonsenso D; Butnaru D; Carter A; Chu H; De Rose C; Diab MM; Ekbom E; El Tantawi M; Fomin V; Frithiof R; Gamirova A; Glybochko PV; Haagsma JA; Haghjooy Javanmard S; Hamilton EB; Harris G; Heijenbrok-Kal MH; Helbok R; Hellemons ME; Hillus D; Huijts SM; Hultström M; Jassat W; Kurth F; Larsson IM; Lipcsey M; Liu C; Loflin CD; Malinovschi A; Mao W; Mazankova L; McCulloch D; Menges D; Mohammadifard N; Munblit D; Nekliudov NA; Ogbuoji O; Osmanov IM; Peñalvo JL; Petersen MS; Puhan MA; Rahman M; Rass V; Reinig N; Ribbers GM; Ricchiuto A; Rubertsson S; Samitova E; Sarrafzadegan N; Shikhaleva A; Simpson KE; Sinatti D; Soriano JB; Spiridonova E; Steinbeis F; Svistunov AA; Valentini P; van de Water BJ; van den Berg-Emons R; Wallin E; Witzenrath M; Wu Y; Xu H; Zoller T; Adolph C; Albright J; Amlag JO; Aravkin AY; Bang-Jensen BL; Bisignano C; Castellano R; Castro E; Chakrabarti S; Collins JK; Dai X; Daoud F; Dapper C; Deen A; Duncan BB; Erickson M; Ewald SB; Ferrari AJ; Flaxman AD; Fullman N; Gamkrelidze A; Giles JR; Guo G; Hay SI; He J; Helak M; Hulland EN; Kereselidze M; Krohn KJ; Lazzar-Atwood A; Lindstrom A; Lozano R; Malta DC; Månsson J; Mantilla Herrera AM; Mokdad AH; Monasta L; Nomura S; Pasovic M; Pigott DM; Reiner RC; Reinke G; Ribeiro ALP; Santomauro DF; Sholokhov A; Spurlock EE; Walcott R; Walker A; Wiysonge CS; Zheng P; Bettger JP; Murray CJL; Vos T
JAMA; 2022 Oct; 328(16):1604-1615. PubMed ID: 36215063
[TBL] [Abstract][Full Text] [Related]
3. Neurobiological basis and risk factors of persistent fatigue and concentration problems after COVID-19: study protocol for a prospective case-control study (VeCosCO).
Verveen A; Verfaillie SCJ; Visser D; Csorba I; Coomans EM; Koch DW; Appelman B; Barkhof F; Boellaard R; de Bree G; van de Giessen EM; Golla S; van Heugten CM; Horn J; Hulst HE; de Jong MD; Kuut TA; van der Maaden T; van Os YMG; Prins M; Slooter AJC; Visser-Meily JMA; van Vugt M; van den Wijngaard CC; Nieuwkerk PT; Knoop H; Tolboom N; van Berckel BNM
BMJ Open; 2023 Jun; 13(6):e072611. PubMed ID: 37399444
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review.
Nasserie T; Hittle M; Goodman SN
JAMA Netw Open; 2021 May; 4(5):e2111417. PubMed ID: 34037731
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characterization of the Persistent COVID-19 Symptoms: A Descriptive Observational Study in Primary Care.
Rodríguez Onieva A; Vallejo Basurte C; Fernández Bersabé A; Camacho Cerro L; Valverde Bascón B; Muriel Sanjuan N; Soto Castro CA; García Morales V; Piedra Ruiz F; Hidalgo Requena A
J Prim Care Community Health; 2023; 14():21501319231208283. PubMed ID: 37947104
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.
Alkodaymi MS; Omrani OA; Fawzy NA; Shaar BA; Almamlouk R; Riaz M; Obeidat M; Obeidat Y; Gerberi D; Taha RM; Kashour Z; Kashour T; Berbari EF; Alkattan K; Tleyjeh IM
Clin Microbiol Infect; 2022 May; 28(5):657-666. PubMed ID: 35124265
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Severity of Symptoms 3 Months After Infection With SARS-CoV-2 Compared to Test-Negative and Population Controls in the Netherlands.
van der Maaden T; Mutubuki EN; de Bruijn S; Leung KY; Knoop H; Slootweg J; Tulen AD; Wong A; van Hoek AJ; Franz E; van den Wijngaard CC
J Infect Dis; 2023 Apr; 227(9):1059-1067. PubMed ID: 36477364
[TBL] [Abstract][Full Text] [Related]
9. Post-COVID-19 Symptoms 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized Patients.
Fernández-de-Las-Peñas C; Rodríguez-Jiménez J; Cancela-Cilleruelo I; Guerrero-Peral A; Martín-Guerrero JD; García-Azorín D; Cornejo-Mazzuchelli A; Hernández-Barrera V; Pellicer-Valero OJ
JAMA Netw Open; 2022 Nov; 5(11):e2242106. PubMed ID: 36378309
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study.
Menges D; Ballouz T; Anagnostopoulos A; Aschmann HE; Domenghino A; Fehr JS; Puhan MA
PLoS One; 2021; 16(7):e0254523. PubMed ID: 34252157
[TBL] [Abstract][Full Text] [Related]
12. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
13. EuCARE-POSTCOVID Study: a multicentre cohort study on long-term post-COVID-19 manifestations.
Varisco B; Bai F; De Benedittis S; Tavelli A; Cozzi-Lepri A; Sala M; Miraglia FG; Santoro MM; Ceccherini-Silberstein F; Shimoni Y; Ravid S; Kozlovski T; König F; Pfeifer N; Shamsara E; Parczewski M; Monforte AD; Incardona F; Mommo C; Marchetti G
BMC Infect Dis; 2023 Oct; 23(1):684. PubMed ID: 37833640
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal course and predictors of health-related quality of life, mental health, and fatigue, in non-hospitalized individuals with or without post COVID-19 syndrome.
Kirchberger I; Meisinger C; Warm TD; Hyhlik-Dürr A; Linseisen J; Goßlau Y
Health Qual Life Outcomes; 2024 Apr; 22(1):32. PubMed ID: 38616282
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infection is associated with self-reported post-acute neuropsychological symptoms within six months of follow-up.
Andronescu LR; Richard SA; Scher AI; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Smith A; Mody RM; Jones MU; Bazan SE; Colombo RE; Colombo CJ; Ewers E; Larson DT; Maves RC; Berjohn CM; Maldonado CJ; English C; Sanchez Edwards M; Rozman JS; Rusiecki J; Byrne C; Simons MP; Tribble D; Burgess TH; Pollett SD; Agan BK
PLoS One; 2024; 19(4):e0297481. PubMed ID: 38626117
[TBL] [Abstract][Full Text] [Related]
17. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study.
Ballouz T; Menges D; Anagnostopoulos A; Domenghino A; Aschmann HE; Frei A; Fehr JS; Puhan MA
BMJ; 2023 May; 381():e074425. PubMed ID: 37257891
[TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
19. Association of SARS-CoV-2 Infection With Psychological Distress, Psychotropic Prescribing, Fatigue, and Sleep Problems Among UK Primary Care Patients.
Abel KM; Carr MJ; Ashcroft DM; Chalder T; Chew-Graham CA; Hope H; Kapur N; McManus S; Steeg S; Webb RT; Pierce M
JAMA Netw Open; 2021 Nov; 4(11):e2134803. PubMed ID: 34783824
[TBL] [Abstract][Full Text] [Related]
20. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study.
Ballering AV; van Zon SKR; Olde Hartman TC; Rosmalen JGM;
Lancet; 2022 Aug; 400(10350):452-461. PubMed ID: 35934007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
